In recent decades, cancer stem cells (CSCs) have been increasingly identified in many
malignancies. CSC-related signaling pathways and their functions provide new strategies …

Importance Hedgehog pathway inhibitors (HPIs) were made available by US Food and Drug
Administration approval in 2012 for vismodegib and 2015 for sonidegib. Both target the …

Adolescents and young adults aged 15 to 39 years who are diagnosed with cancer (AYA
survivors) undergo a range of therapies for cancer cure but subsequently may be at risk of …

Background Aberrant activation of the Hedgehog (Hh) pathway is a key driver in the
pathogenesis of basal cell carcinomas (BCCs), including patients with BCC nevus syndrome …

Hedgehog pathway inhibitors (HHIs) have broadened the treatment options available for
patients with advanced basal cell carcinoma (BCC) for whom traditional therapeutic …

A female patient with xeroderma pigmentosum and multiple basal cell carcinomas was
treated with a hedgehog pathway inhibitor (vismodegib), which successfully treated the …

Smoothened inhibitors represent the first class of targeted drugs approved for use in
advanced and metastatic basal cell carcinoma. For many patients with limited treatment …

Some patients with basal cell carcinoma develop a large number of basal cell carcinomas
during their lives. The most common underlying genetic disease that causes multiple basal …

There are a number of barriers that result in cancer patients not being referred for
oncofertility care, which include knowledge about reproductive risks of antineoplastic …

Basal cell carcinoma (BCC), when untreated, causes significant morbidity and mortality.
Challenging tumors are regularly reviewed in multimodality tumor boards and are classified …